EDAP TMS announced that the first patient has been treated in a Phase I/II PULS Trial, evaluating its proprietary High Intensity Focused Ultrasound (HIFU) technology for the treatment of pancreatic tumors. The trial is sponsored by the Centre Léon Bérard in Lyon, France.
The Phase I of the multicenter study aims to evaluate the tolerance of intraoperative HIFU intervention on pancreatic lesions, with Phase II focusing on preliminary efficacy. This initiative represents a new approach for treating pancreatic cancer, a disease with a five-year survival rate of 11.5% based on 2012-2018 data.
This milestone demonstrates EDAP's commitment to applying focused ultrasound therapy in areas of significant unmet medical need beyond prostate cancer. The development of new treatments for pancreatic cancer is vital given the low proportion of patients who can benefit from surgery and the scarcity of alternative therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.